scispace - formally typeset
A

Alfredo Alberti

Researcher at University of Padua

Publications -  344
Citations -  13216

Alfredo Alberti is an academic researcher from University of Padua. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 62, co-authored 342 publications receiving 12875 citations. Previous affiliations of Alfredo Alberti include University of Milan.

Papers
More filters
Journal ArticleDOI

Management of hepatitis C.

TL;DR: This review addresses the main recent developments in the field of basic and clinical research on HCV, with particular reference to the clinical management of acute and chronic hepatitis C.
Journal ArticleDOI

Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C

TL;DR: Stepwise combination of non-invasive markers of liver fibrosis improves the diagnostic performance in chronic hepatitis C and need for liver biopsy is reduced by 50-70% but cannot be completely avoided.
Journal ArticleDOI

Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy

TL;DR: In this paper, a set of algorithms that combine sequentially indirect non-invasive markers of liver fibrosis, reaching 90%-95% diagnostic accuracy with significant reduction in the need for liver biopsy, was proposed.
Journal ArticleDOI

Clinical and virological profiles in patients with multiple hepatitis virus infections.

TL;DR: A reciprocal inverse relation between HBV and HCV replication is indicated and the biochemical activity and the histological severity of liver disease were lower in HCV RNA-positive/HBV DNA-negative patients, compared with HCVRNA (serum)-negative/HBv DNA-positive cases.
Journal ArticleDOI

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

Eugene R. Schiff, +98 more
TL;DR: Adefovir dipivoxil is effective and safe in wait‐listed or post–liver transplantation chronic hepatitis B patients with lamivudine‐resistant HBV and prevents graft reinfection with or without HBIg.